🟢 Insulet is trading 4.2% up today despite broader healthcare sector weakness

Insulet is trading 4.2% higher at $166.13, moving notably above its recent $150–$160 range despite a lack of fresh company-specific catalysts.

• No new earnings, FDA updates, M&A activity, or major analyst calls have been reported for the July 16, 2026, session.
• The stock is outperforming the broader healthcare sector, which is generally weaker today, suggesting the move may be driven by technical buying or idiosyncratic demand.
• The price action marks a significant breakout from the stock's established narrow trading range.